{
    "clinical_study": {
        "@rank": "148035", 
        "arm_group": [
            {
                "arm_group_label": "FE 992097", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety and effectiveness of intranasal FE\n      992097 in children and adults with Prader-Willi Syndrome."
        }, 
        "brief_title": "Treatment of Hyperphagia Behavioral Symptoms in Children and Adults Diagnosed With Prader-Willi Syndrome", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Hyperphagia in Prader-Willi Syndrome", 
        "condition_browse": {
            "mesh_term": [
                "Behavioral Symptoms", 
                "Hyperphagia", 
                "Prader-Willi Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female 10-18 years of age (both inclusive)\n\n          -  Genetically confirmed diagnosis of Prader-Willi Syndrome\n\n          -  Determined to be in nutritional phase 3 by clinical assessment based on Miller et al,\n             2011\n\n        Exclusion Criteria:\n\n          -  Known genetic, hormonal, or chromosomal cause of cognitive impairment other than\n             Prader-Willi Syndrome\n\n          -  Presence of currently active psychotic symptoms\n\n          -  Presence of any cardiovascular disorders, epilepsy, frequent migraines or severe\n             asthma\n\n          -  Previous diagnosis of autism spectrum disorder by a qualified healthcare provider\n\n          -  Prior or concomitant use of a selective serotonin reuptake inhibitor (SSRI) or\n             selective norepinephrine reuptake inhibitor (SNRI), antipsychotic medication,\n             wakefulness-promoting drug, or thyroid hormone unless dosage has been stable \u22656\n             months at time of screening"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "10 Years"
        }, 
        "enrollment": {
            "#text": "38", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01968187", 
            "org_study_id": "000114"
        }, 
        "intervention": [
            {
                "arm_group_label": "FE 992097", 
                "intervention_name": "FE 992097", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 9, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Gainesville", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "Florida University"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mineola", 
                        "country": "United States", 
                        "state": "New York"
                    }, 
                    "name": "Winthrop University"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee"
                    }, 
                    "name": "Vanderbilt University"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "DK0-Disclosure@ferring.com", 
            "last_name": "Clinical Development Support"
        }, 
        "overall_official": {
            "affiliation": "Ferring Pharmaceuticals", 
            "last_name": "Clinical Development Support", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in total hyperphagia score as measured by a Hyperphagia for Prader-Willi Syndrome Questionnaire", 
            "safety_issue": "No", 
            "time_frame": "from day 1 to day 15"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01968187"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Clinical Global Impression - Improvement score", 
                "safety_issue": "No", 
                "time_frame": "at day 15"
            }, 
            {
                "measure": "Change in Hyperphagia for Prader-Willi Syndrome Questionnaire domain scores", 
                "safety_issue": "No", 
                "time_frame": "from day 1 to day 15"
            }, 
            {
                "measure": "Change in Children's Yale-Brown Obsessive Compulsive Scale score", 
                "safety_issue": "No", 
                "time_frame": "from screening to day 15"
            }, 
            {
                "measure": "Change in the food domain of the Reiss Profile", 
                "safety_issue": "No", 
                "time_frame": "from screening to day 15"
            }
        ], 
        "source": "Ferring Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ferring Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}